Premier Alternatives

RxAnte

Portland, ME · Founded 2011 · Acquired/Merged (Operating Subsidiary)

Provider of predictive analytics and targeted clinical programs intended to improve medication prescribing and adherence. RxAnte is based in Portland, ME and was founded in 2011. Its last known valuation is $28.9 million (Nov 2020). It has raised $49.8 million across 1 recorded round; the latest was a $10.9 million debt round in Oct 2020.

Last price · $/share
—
Implied valuation
$28.9M
Total raised
$49.8M
Last round
Debt
Oct 2020

RxAnte key facts

  • Provider of predictive analytics and targeted clinical programs intended to improve medication prescribing and adherence.
  • RxAnte’s last known valuation is $28.9M (Nov 2020).
  • It has raised $49.8M across 1 recorded rounds; the latest was Debt ($10.9M) in Oct 2020.
  • Notable investors include First Trust Capital Partners, PNC Erieview Capital, Primus Capital, Trinity Capital (Phoenix).
  • RxAnte has filed 2 Form Ds with the SEC since 2020, most recently May 2022 ($10.9M sold to 7 investors).
  • Status: Acquired/Merged (Operating Subsidiary).
Free account
More of RxAnte with a free account
  • ·Watch RxAnte: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

RxAnte funding rounds

1 rounds
Oct 2020Debt$10.9MSEC filing▮
Full funding history →

RxAnte valuation

RxAnte's last known valuation is $28.9 million, from Nov 2020. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

How much has RxAnte raised?

RxAnte has raised $49.8 million in total; 1 of its rounds is on record. The largest on record was a $10.9 million debt round in Oct 2020.

RxAnte has filed 2 Form Ds with the SEC since 2020, most recently in May 2022 ($10.9 million sold to 7 investors).

RxAnte investors

4 investors are on record for RxAnte, including First Trust Capital Partners, PNC Erieview Capital, Primus Capital and Trinity Capital (Phoenix). The debt round in Oct 2020 drew 7 investors.

About RxAnte

Provider of predictive analytics and targeted clinical programs intended to improve medication prescribing and adherence. The company's platform specializes in providing high-value pharmacy services and improving medication prescribing, adherence, clinical quality scores, and total cost of care, enabling clients with a good pharmacy experience while working with their prescribers and caregivers to make regimens safer, simpler, and more affordable.

Sector
Healthcare
HQ
Portland, ME, United States
Founded
2011
Employees
95
Ownership
Acquired/Merged (Operating Subsidiary)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$28.9M

RxAnte’s last known valuation, Nov 2020. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.